Indication. Recent NICE guidance (NICE NG 87 March 2018) now advocates that medication can be considered for children aged 5 years and above. Prior to this, 6 years old was the recommendation and hence this makes prescribing in 5 year olds unlicensed but is supported by NICE if deemed clinically appropriate. Lisdexamfetamine is licensed in children aged 6 years of age and over when response to previous methylphenidate treatment is considered clinically inadequate. Dexamfetamine is licensed for the treatment of refractory ADHD in children over 3 years.
Appears in 3 contracts
Sources: Shared Care Agreement, Shared Care Agreement, Shared Care Agreement